Patterns of antihypertensive drug use, the cost of this care and potential savings with changes of treatment patterns, were studied for all hypertensives treated at US Veterans Affairs (VA) medical facilities for fiscal years 1995 and 1996.
Data was aggregated by individual medication as well as by antihypertensive drug class.
Cost estimates were based on median cost and number of units for each dosage form of each medication dispensed at all facilities.
Potential savings were estimated by substituting bêta-blockers or diuretics for calcium antagonists.
In a subset of patients the prevalence of hypertension, and among hypertensives the prevalence of coronary artery disease, congestive heart failure, and diabetes mellitus, was determined.
For these patients, patterns of treatment by antihypertensive drug class was examined.
For all VA facilities, of the 10 most frequently prescribed antihypertensives in 1995, four were calcium antagonists, two angiotensin converting enzyme (ACE) inhibitors, two bêta-blockers, and two diuretics.
In 1996, this was changed by the addition of an ACE inhibitor and the subtraction of a diuretic combination.
Calcium antagonists accounted for 37% of treatment days in 1995 and 35% in 1996, ACE inhibitor use went from 34% to 36%, bêta-blockers from 17% to 18%, and diuretic use remained at 12%. In 1996, approximately 86.6 million dollars were spent on calcium antagonists, 51.8 million on ACE inhibitors, 7.9 million on bêta-blockers, and 3. (...)
Mots-clés Pascal : Hypertension artérielle, Traitement, Chimiothérapie, Antihypertenseur, Homme, Exploration, Prescription médicale, Coût, Economie santé, Ancien combattant, Etats Unis, Amérique du Nord, Amérique, Appareil circulatoire pathologie
Mots-clés Pascal anglais : Hypertension, Treatment, Chemotherapy, Antihypertensive agent, Human, Exploration, Medical prescription, Costs, Health economy, Veteran, United States, North America, America, Cardiovascular disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0038813
Code Inist : 002B02F05. Création : 31/05/1999.